abrdn Life Sciences Investors (NYSE:HQL) Stock Price Down 0.1% – Here’s Why

abrdn Life Sciences Investors (NYSE:HQL)’s stock price dropped 0.1% during mid-day trading on Wednesday. The company traded as low as $17.32 and last traded at $17.5450. 92,927 shares were traded during mid-day trading, a decline of 30% from the average daily volume of 133,602 shares. The stock had previously closed at $17.56.

abrdn Life Sciences Investors Trading Down 0.1%

The stock has a 50-day moving average price of $20.11 and a 200 day moving average price of $18.77.

abrdn Life Sciences Investors Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Monday, August 24th were paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 14.1%. The ex-dividend date of this dividend was Monday, August 24th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Independent Financial Group LLC bought a new position in abrdn Life Sciences Investors in the first quarter valued at approximately $211,000. WNY Asset Management LLC bought a new stake in shares of abrdn Life Sciences Investors during the first quarter worth $239,000. Citadel Advisors LLC acquired a new stake in shares of abrdn Life Sciences Investors during the second quarter worth $287,000. Wedbush Securities Inc. raised its holdings in shares of abrdn Life Sciences Investors by 50.6% during the second quarter. Wedbush Securities Inc. now owns 15,960 shares of the company’s stock worth $319,000 after acquiring an additional 5,360 shares during the period. Finally, NewEdge Advisors LLC raised its holdings in shares of abrdn Life Sciences Investors by 17.6% during the first quarter. NewEdge Advisors LLC now owns 23,788 shares of the company’s stock worth $387,000 after acquiring an additional 3,562 shares during the period. Institutional investors own 32.21% of the company’s stock.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a diversified, closed-end investment company focused on the life sciences sector. The fund seeks long-term capital appreciation by investing in companies involved in biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services and related industries.

Its portfolio may include both publicly traded and privately held businesses across various stages of development, from emerging companies developing new therapies and technologies to more established healthcare enterprises.